Researchers identify 5 genetic variations associated with risk of venous thrombosis in womenFebruary 07, 2007Researchers have identified new genetic variations that may be associated with the risk of developing nonfatal venous thrombosis in postmenopausal women, according to a study in the February 7 issue of JAMA. Deep vein thrombosis (blood clots in the thigh or leg) and pulmonary embolism (blood clots in the arteries leading to the lungs) cause significant illness and death in adult women, according to the background information in the article. The authors note that despite improved preventive treatments in high-risk patients, the incidence of venous thrombosis (VT) has not decreased. In this study, Nicholas L. Smith, Ph.D., M.P.H., from the University of Washington, Seattle, and colleagues examined the association of common genetic variation in 24 clotting-related candidate genes with the risk of first-time VT in postmenopausal women. Study participants were 349 perimenopausal and postmenopausal women 30 to 89 years of age who sustained a first VT event between January 1995 and December 2002. The control group of 1,680 women included perimenopausal and postmenopausal women of the same age range who had no prior history of deep vein thrombosis or pulmonary embolism. Through blood samples taken from the study participants, the researchers analyzed genetic markers called haplotypes and changes in the DNA sequence called single nucelotide polymorphisms (SNP). "Only the tissue factor pathway inhibitor gene demonstrated global association with risk. Five significant SNP associations were identified across three of the candidate genes (factors V, XI and protein C) in SNP analyses," the researchers report. Two of those associations had been previously reported. The researchers note that another 22 variants across 15 genes were also identified and classify them as "interesting associations." "After accounting for multiple testing, five SNPs associated with VT risk were identified, three of which have not been previously reported. Replication of these novel associations in other populations is necessary to corroborate these findings and identify which genetic factors may influence VT risk in postmenopausal women," the authors conclude. JAMA and Archives Journals |
|||||||||||||||||||||
| Related Thrombosis Current Events and Thrombosis News Articles When seconds count: Interventional radiology treatment for pulmonary embolism saves lives Catheter-directed therapy or catheter-directed thrombolysis-an interventional radiology treatment that uses targeted image-guided drug delivery with specially designed catheters to dissolve dangerous blood clots in the lungs-saves lives and should be considered a first-line treatment option for massive pulmonary embolism, note researchers in the November Journal of Vascular and Interventional Radiology. Drugs to treat anemia in cancer patients linked to thromboembolism Medications frequently given to cancer patients to reduce their risk of anemia are associated with an increased risk of deep vein thrombosis or pulmonary embolism, according to new research led by Dawn Hershman, M.D, M.S., co-director of the breast cancer program at the Herbert Irving Comprehensive Cancer Center at NewYork-Presbyterian Hospital/Columbia University Medical Center. Clots traveling from lower veins may not be the cause of pulmonary embolism in trauma patients A report from a team of Massachusetts General Hospital (MGH) physicians calls into question the longstanding belief that pulmonary embolism (PE) - the life-threatening blockage of a major blood vessel in the lungs - is caused in trauma patients by a blood clot traveling from vessels deep within the legs or lower torso. Blood clots in lungs might not always originate in deep veins of legs and pelvis in trauma patients Few trauma patients who develop potentially deadly blood clots in the lungs (pulmonary embolism) also have clots in the deep veins of their pelvis and legs (deep venous thrombosis), challenging commonly held beliefs about the association between the two conditions. Drug-eluting stents better than bare-metal stents for heart attack patients Late-breaking data from the landmark HORIZONS-AMI clinical trial, presented at the 21st annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, demonstrated that after two years, in heart attack patients, the use of a drug-eluting stent (paclitaxel) was safer and more effective than a bare-metal stent; and that the administration of the anticoagulant medication bivalirudin enhanced safety and efficacy compared to the use of heparin + GPIIb/IIIa inhibitors. SPIRIT IV trial shows everolimus stent sets new standard for event-free survival Late-breaking data from SPIRIT IV, a large-scale multi-center study of nearly 4,000 patients in the U.S., shows that an everolimus-eluting stent demonstrated enhanced safety and efficacy in the treatment of de novo native coronary artery lesions when compared to a paclitaxel-eluting stent, and showed that "low late loss" may be achieved with drug-eluting stents without sacrificing safety. Few complications 1 year after aortic valve implantation Research presented at the 21st annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation (CRF), demonstrated an "exceptionally low" rate of complications one year after implantation of transcatheter aortic valve prostheses. Image-guided treatment for deep venous thrombosis could improve patients' long-term outcomes Deep Venous Thrombosis (DVT) is a serious condition that involves the formation of a blood clot inside of a deep vein usually in the legs. A patient with DVT is typically treated with anticoagulants (blood thinners) however researchers have found that image-guided interventional radiology procedures may play a more central role in the long-term treatment of DVT. Results from the Kyoto heart study The KYOTO HEART Study, which took place in Japan between January 2004 and January 2009, shows that the addition of valsartan to conventional antihypertensive treatment to improve blood pressure control is associated with an improved cardiovascular outcome in Japanese hypertensive patients at high risk of CVD events. University of Maryland researchers identify gene variant linked to effectiveness of plavix Researchers at the University of Maryland School of Medicine have identified a common gene variant carried by as many as a third of the general population that is believed to play a major role in determining why people do not respond to a popular anti-clotting medication, Plavix. More Thrombosis Current Events and Thrombosis News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||